NCT06271057招募中2 期
Golcadomide (BMS-986369) Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse
The Lymphoma Academic Research Organisation13 个研究点 分布在 1 个国家目标入组 65 人开始时间: 2024年6月14日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 65
- 试验地点
- 13
- 主要终点
- Complete metabolic response rate (CMR rate)
研究概览
简要总结
This study is an open-label, multicenter, proof of concept, phase 2 trial. Patients will be recruited over 18 months. Safety analysis will be performed with a stop of the enrollment after 3 patients have either 1 complete treatment cycle or permanently discontinued treatment whichever occurs first.
Approximatively 65 patients with aggressive large B-cell lymphoma (LBCL) (including diffuse large B-cell lymphoma (DLBCL), Primary mediastinal B-cell lymphoma (PMBCL), any transformed follicular or marginal zone lymphoma, high-grade B-cell lymphoma (HGBL)) will be enrolled in the study.
The duration of treatment with golcadomide (CELMoD) is 24 weeks with 6 cycles of 28 days (4 weeks), starting at 5 days after CAR-T cells infusion.
The primary objective of the study is to estimate the efficacy of golcadomide administered post-anti-CD19 CAR T-cell infusion, Efficacy determination will be based upon the primary endpoint of complete metabolic response (CMR) rate at 3 months after infusion of anti-CD19 CAR T-cell assessed by study investigator.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient who understood and voluntarily signed and dated an informed consent prior to any study-specific assessments/procedures being conducted
- •Adults patients (≥ 18-year-old at the time of signing the informed consent form; no upper age limit)
- •Eligible for any commercialized market authorized anti-CD19 CAR T-cells
- •Performance Status 0, 1, or 2
- •With aggressive large B-cell lymphoma, including:
- •diffuse large B-cell lymphoma
- •Primary mediastinal B-cell lymphoma
- •Any transformed follicular or marginal zone lymphoma
- •high-grade B-cell lymphoma (HGBL) Note: patients with Central Nervous System (CNS) involvement could be included but not patients with primary CNS lymphoma
- •Available biopsy for centralized review
- •With a CAR T-cells indication as soon as 2nd line treatment no later than in 4th line, previously validated by the multidisciplinary tumor board Note: Any treatment performed prior to leukapheresis is considered a line of treatment
- •Total MetabolicTumor Volume (TMTV) > 80 ml, measured by centralized review, on standard18FDG-PET (positron emission tomography) done just before starting CAR T-cells procedure (i.e., D-13 +/- 4 days before lymphodepletion)
- •Creatinine clearance (as estimated by Modification of Diet in Renal Disease (MDRD) if > 60-year-old or Cockcroft-Gault if <60yo) >45 mL/min,
- •Adequate hepatic function:
- •aspartate aminotransferase/alanine aminotransferase (ALT/AST) ≤ 3.0 x ULN. (Note: In the case of documented liver involvement by lymphoma, ALT/AST must be ≤ 5.0 x ULN)
- •Serum total bilirubin ≤ 2.0 mg/dL (34 μmol/L) (Note: In the case of Gilbert's syndrome, or documented liver or pancreatic involvement by lymphoma, serum total bilirubin must be ≤ 3.0 mg/dL (51 μmol/L))
- •Patient covered by any social security system (France)
- •Patient who understands and speaks one of the country official languages, unless local regulation authorizes independent translators
- •Contraception:
- •For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use two adequate methods of contraception, including at least one highly effective method, as soon as consent is signed, during the treatment period (including periods of treatment interruption), and for at least 28 days after the last dose of golcadomide, Women must refrain from donating eggs during this same period.
排除标准
- •History of malignancy other than non-melanoma skin cancer or carcinoma in situ (eg, cervix, bladder, breast) unless disease free for at least 3 years
- •Presence or suspicion of fungal, bacterial, viral, or other infection that is uncontrolled or requiring IV antimicrobials for management; simple urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to active treatment and after consultation with the sponsor's medical monitor
- •History of human immunodeficiency virus (HIV) infection or acute or chronic active hepatitis B or C infection; subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America guidelines or applicable country guidelines
- •Significant pulmonary function impairment and oxygen saturation (SaO2) < 92% on room air
- •Significant cardiovascular disease such as New York Heart Association Class III or IV or Objective Class C or D cardiac disease (see appendix 07)
- •History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 6 months of enrollment
- •History of severe immediate hypersensitivity reaction to any of the agents used in this study
- •Current treatment with strong CYP3A4/5 modulators (see appendix 13)
- •Pregnant, planning to become pregnant or lactating Women of Child Bearing Potential
- •Any significant medical conditions, laboratory abnormality or psychiatric illness likely to interfere with participation in this clinical study (according to the investigator's decision)
- •Person deprived of his/her liberty by a judicial or administrative decision
- •Person hospitalized without consent
- •Adult person under legal protection
研究组 & 干预措施
golcadomide post CAR T-cells
Experimental
0.3 mg - Per Os - every week - 6 months
干预措施: golcadomide (Drug)
结局指标
主要结局
Complete metabolic response rate (CMR rate)
时间窗: 3 months
efficacy of golcadomide administered post-anti-CD19 CAR T-cell infusion
次要结局
- Event-free survival (EFS)(2 years)
- Objective response rate (ORR)(at 1 month and 3 months)
- Time To Next anti-Lymphoma Treatment (TTNLT)(2 years)
- Overall survival (OS)(2 years)
- Complete response rate (CRR)(at 1 Month, 6 Months, 1 year, and 2 years)
- Duration of response (DR)(2 years)
- Progression-free survival (PFS)(2 years)
- Incidence of Adverse Events and Serious Adverse events(2 years)
- Objective response rate (ORR)(at 1 month, 3 months, 6 months, 1 year and 2 years, from CAR-T infusion)
研究者
研究点 (13)
Loading locations...
相似试验
进行中（未招募）
1 期
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk And/or Relapsed/refractory Neuroblastoma or Other GD2-positive Solid TumorsNeuroblastoma RecurrentGD2-positive Solid TumorsNeuroblastomaEwing SarcomaOsteosarcomaSarcomaNCT03373097Bambino Gesù Hospital and Research Institute42
招募中
1 期
GD2-CAR T Cells for Pediatric Brain TumoursMedulloblastoma, ChildhoodEmbryonal TumorHigh Grade GliomaBrain Tumor AdultBrain Tumor, PediatricDiffuse Intrinsic Pontine GliomaDiffuse Midline GliomaNCT05298995Bambino Gesù Hospital and Research Institute54
进行中（未招募）
1 期
Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive CancersPancreatic CancerGastric CancerNCT04404595CARsgen Therapeutics Co., Ltd.110
Unknown
早期 1 期
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALLB-cell Acute Lymphoblastic LeukemiaNCT04129099Hebei Yanda Ludaopei Hospital18
Unknown
早期 1 期
A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHLB-cell Non Hodgkin LymphomaNCT04412174Hebei Yanda Ludaopei Hospital18